bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational ProgressBusiness Wire • 05/09/22
Will Bluebird Bio (BLUE) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/27/22
Gene-therapy biotech Bluebird Bio is set to lay off 30% of the company after warning it could struggle to survive through 2022Business Insider • 04/05/22
Bluebird bio to lay off nearly one-third of its employees as part of restructuringMarket Watch • 04/05/22
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the USBusiness Wire • 04/05/22
bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate UpdateBusiness Wire • 03/04/22
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/15/22
Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet ApprovalSeeking Alpha • 02/07/22
FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene TherapiesBenzinga • 01/18/22